

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/48109 A2

(51) International Patent Classification⁷: **C07D 211/94**,
C08F 2/00

(74) Common Representative: **CIBA SPECIALTY CHEMI-
CLAS HOLDING INC.**; Patentabteilung, Klybeckstrasse
141, CH-4057 Basel (CH).

(21) International Application Number: PCT/EP01/13071

(22) International Filing Date:
12 November 2001 (12.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00811191.6 14 December 2000 (14.12.2000) EP

(71) Applicant (*for all designated States except US*): **CIBA
SPECIALTY CHEMICALS HOLDING INC.** [CH/CH];
Klybeckstrasse 141, CH-4057 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FUSO, Francesco**
[IT/CH]; Bienenweg 8, CH-4106 Therwil (CH). **WUN-
DERLICH, Wiebke** [DE/IT]; Via Valdossola 28, I-40134
Bologna (IT). **KRAMER, Andreas** [CH/CH]; Rue Os-
car-Pathé 45, CH-3280 Meyriez (CH). **FINK, Jochen**
[DE/DE]; Kurt-Schumacherstrasse 16, 69226 Nussloch
(DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, WITH GLYCIDYL OR ALKYL CARBONYL GROUPS AS FUNCTIONAL INITIATORS FOR CONTROLLED RADICAL POLYMERIZATION

(57) Abstract: The present invention relates to selected glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds forming an open chain or cyclic ketal structure, a polymerizable composition comprising a) at least one ethylenically unsaturated monomer and b) a glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine nitroxide initiator compound. Further aspects of the present invention are a process for polymerizing ethylenically unsaturated monomers and the use of glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine nitroxide initiators for radical polymerization.

WO 02/48109 A2

N-Alkoxy-4,4-Dioxy-Polyalkyl-Piperidine Compounds, with Glycidyl or Alkylcarbonyl Groups as Functional Initiators for Controlled Radical Polymerization

The present invention relates to selected glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds forming an open chain or cyclic ketal structure, a polymerizable composition comprising a) at least one ethylenically unsaturated monomer and b) a glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine nitroxide initiator compound. Further aspects of the present invention are a process for polymerizing ethylenically unsaturated monomers and the use of glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine nitroxide initiators for radical polymerization.

The compounds of the present invention provide polymeric resin products having low polydispersity and the polymerization process proceeds with good monomer to polymer conversion efficiency. In particular, this invention relates to stable free radical-mediated polymerization processes which provide homopolymers, random copolymers, block copolymers, multiblock copolymers, graft copolymers and the like, at enhanced rates of polymerization and enhanced monomer to polymer conversions.

US-A-4 581 429 to Solomon et al., issued April 8, 1986, discloses a free radical polymerization process which controls the growth of polymer chains to produce short chain or oligomeric homopolymers and copolymers, including block and graft copolymers. The process employs an initiator having the formula (in part) $R'R''N-O-X$, where X is a free radical species capable of polymerizing unsaturated monomers. The reactions typically have low conversion rates. Specifically mentioned radical $R'R''N-O\bullet$ groups are derived from 1,1,3,3-tetraethylisindoline, 1,1,3,3-tetrapropylisindoline, 2,2,6,6-tetramethylpiperidine, 2,2,5,5-tetramethylpyrrolidine or di-t-butylamine. However, the suggested compounds do not fulfill all requirements. Particularly the polymerization of acrylates does not proceed fast enough and/or the monomer to polymer conversion is not as high as desired.


The radical initiators, polymerization processes and resin products of the present invention have an additional glycidyl or carbonyl group, which can be used for further reactions. The resulting resins are useful in many applications.

- 2 -

The glycidyl or alkylcarbonyl group of the present initiators remains essentially unchanged during the radical polymerization reaction. Therefore the radical initiators of the present invention offer the possibility, after the radical polymerization is accomplished or stopped, to react the glycidyl group of the oligomers or polymers in a second step with nucleophiles such as alcohols, mercaptanes, amines, metal organic compounds or the like, thereby changing the properties of the oligomers or polymers.

The glycidyl group of the initiators can also be reacted in a first step for example by anionic polymerization in the presence of for example dicyandiamide, butyl-Lithium or other strong bases leading to oligomeric/polymeric radical initiators.

S. Kobatake et al, *Macromolecules* 1997, 30, 4238-4242 and in WO 97/36894 disclose the anionic polymerization of butadiene in the presence of compound (a) which contains a glycidyl group in a side chain. This compound acts as a terminating reagent for the anionic polymerization of butadiene.



The resulting macromolecule can be further used as a macroinitiator for radical polymerization and for preparing block copolymers containing a polylbutadiene segment. Typical copolymers which can be produced are acrylonitrile/butadiene/styrene (ABS) copolymers.

The present invention provides initiators for radical polymerization which contain the glycidyl or alkylcarbonyl group attached to the phenyl group. The initiators show a high reactivity, good rates of polymerization and good monomer to polymer conversions.

The remaining glycidyl or carbonyl group is highly reactive towards nucleophiles and can readily be transformed into other chemical groups if desired.

The compounds of the present invention are also useful as terminating agents in the anionic polymerization of for example butadiene as described in WO 97/36894. With the instant compounds termination of anionic polymerization of for example butadiene proceeds fast and complete.

Glycidyl or carbonyl functional alkoxyamines containing a tetramethyl-piperidine group and their use as functionalized radical initiators/regulators have already been described in WO 99/46261. The instant compounds differ from those disclosed in WO 99/46261 in that they have a ketal structure in 4 position of the piperidine moiety. Such compounds and their use as polymerization initiators/regulators have neither been disclosed as specific compounds nor generically in the prior art.

It has now been found, that amongst those 2,2,6,6-tetraalkylpiperidines described in the prior art those are of particular value which are derivatives of 2,2,6,6 tetramethyl piperidine, 2,2 diethyl-6,6 dimethyl piperidine and of 2,6-diethyl-2,3,6-trimethyl piperidine which are substituted in the 4 position by two oxygen atoms forming an open chain or cyclic ketal structure.

The ketal structure in 4 position ensures high thermal stability which is important for storage, particularly at elevated temperatures. The ketal structure is thermally significantly more stable compared to the corresponding 4-oxo compound.

The compounds exhibit an unchanged initiating/regulating activity even after storage at elevated temperatures as for example used in conventional stability tests.



Another problem associated with nitroxyl or nitroxyl ether mediated free radical polymerization is the formation of a significant color of the resulting polymer. The compounds of the present invention which have a ketal structure in 4-position impart less color to the polymer compared to other prior art compounds of similar structure.

The steric hindrance introduced by the two diethyl groups instead of two methyl groups further leads to an optimized balance in terms of stability of the compounds, initiating activity and control of polymerization.


The particular substitution pattern in 2 and 6 position of the piperidine ring allows high monomer to polymer conversions in short times and low polydispersities which are generally below 2. High monomer to polymer conversions are even achieved with acrylates, such as ethyl- or butyl-acrylate. The temperature necessary to achieve high conversion in short times may be for example as low as 120° C.

The present invention provides compounds useful as initiators/regulators for controlled radical polymerization which in addition have a highly reactive functional group allowing polymer analogous reactions or anionic polymerization termination, which can be adjusted in their initiating/controlling efficiency by adjusting the steric hindrance at the nitrogen atom and which have an excellent storage stability and impart none or only little color to the final polymer.

The compounds of the present invention are novel and consequently one subject of the instant invention is a compound of formula Ia, IIa or IIIa



wherein

D is a group  or a group C(O)-R₁₃;

- 5 -

R_{13} is phenyl or C_1 - C_{18} alkyl;


m is 1, 2 or 3;

n is 1 or 2;

if n is 1

Y and Y' are independently C_1 - C_{12} alkyl, C_3 - C_{12} alkenyl, C_3 - C_{12} alkinyl, C_5 - C_8 cycloalkyl, phenyl, naphthyl, C_7 - C_9 phenylalkyl; or

Y and Y' together form one of the bivalent groups $-C(R_1)(R_2)-CH(R_3)-$, $CH(R_1)-CH_2-C(R_2)(R_3)-$, $-CH(R_2)-CH_2-C(R_1)(R_3)-$, $-CH_2-C(R_1)(R_2)-CH(R_3)-$, o -phenylene, 1,2-cyclohexylen, or




R_1 is hydrogen, C_1 - C_{12} alkyl, $COOH$, $COO-(C_1-C_{12})$ alkyl or CH_2OR_4 ;

R_2 and R_3 are independently hydrogen, methyl ethyl, $COOH$ or $COO-(C_1-C_{12})$ alkyl;

R_4 is hydrogen, C_1 - C_{12} alkyl, benzyl, or a monovalent acyl residue derived from an aliphatic, cycloaliphatic or aromatic monocarboxylic acid having up to 18 carbon atoms;

if n is 2

Y and Y' together form one of the tetravalent groups



Q is a bisacyl residue which is derived from a C_2 - C_{12} dicarboxylic acid or C_1 - C_{12} alkylene;

Z is C₁-C₁₂alkylene;

the R₁₂ are independently of each other H or CH₃.

C₁-C₁₈alkyl can be linear or branched. Examples are methyl, ethyl, propyl, isopropyl, butyl, 2-butyl, isobutyl, t-butyl, pentyl, 2-pentyl, hexyl, heptyl, octyl, 2-ethylhexyl, t-octyl, nonyl, decyl, undecyl, dodecyl, heptadecyl or octadecyl.

Alkenyl having from 3 to 12 carbon atoms is a branched or unbranched radical, for example propenyl, 2-butenyl, 3-butenyl, isobutenyl, n-2,4-pentadienyl, 3-methyl-2-butenyl, n-2-octenyl, n-2-dodecenyl, isododecenyl.

Alkynyl having from 3 to 12 carbon atoms is a branched or unbranched radical, for example propynyl ($\text{—CH}_2\text{—C}\equiv\text{CH}$), 2-butylnyl, 3-butylnyl, n-2-octynyl or n-2-dodecynyl.

Examples of alkoxy are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, isopentoxy, hexoxy, heptoxy or octoxy.

C₇-C₉phenylalkyl is for example benzyl, α -methylbenzyl, α,α -dimethylbenzyl or 2-phenylethyl, benzyl is preferred.

C₁-C₁₂alkylene is a branched or unbranched radical, for example methylene, ethylene, propylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, decamethylene or dodecamethylene.

C₅-C₈cycloalkyl is for example cyclopentyl, cyclohexyl, cycloheptyl, methylcyclopentyl or cyclooctyl.


Examples of a monocarboxylic acid having up to 18 carbon atoms are formic acid, acetic acid, propionic acid, the isomers of valeric acid, methyl ethyl acetic acid, trimethyl acetic acid, capronic acid, lauric acid or stearic acid. Examples for unsaturated aliphatic acids are acrylic acid, methacrylic acid, crotonic acid, linolic acid and oleic acid.

Typical examples of cycloaliphatic carboxylic acids are cyclohexane carboxylic acid or cyclopentane carboxylic acid.


Examples of aromatic carboxylic acids are benzoic acid, salicylic acid or cinnamic acid.

Examples of dicarboxylic acids are oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, sebacic acid, fumaric acid, maleic acid, phthalic acid, isophthalic acid, terephthalic acid.

Preferred is a compound wherein in the formulae Ia, IIa or IIIa D is a group



Particularly preferred is a compound of formula Ia, IIa or IIIa wherein



m is 1;

n is 1 ;

Y and Y' are independently C₁-C₁₂alkyl, C₃-C₁₂alkenyl, phenyl or benzyl; or


Y and Y' together form one of the bivalent groups -C(R₁)(R₂)-CH(R₃)-, CH(R₁)-CH₂-C(R₂)(R₃)-, -CH(R₂)-CH₂-C(R₁)(R₃)-, -CH₂-C(R₁)(R₂)-CH(R₃)-, -CH₂-CH=CH-CH₂- or ;
wherein

R₁ is hydrogen, C₁-C₁₂alkyl, COO-(C₁-C₁₂)alkyl or CH₂OR₄;

R₂ and R₃ are independently hydrogen, methyl ethyl, or COO-(C₁-C₁₂)alkyl;

R₄ is hydrogen, C₁-C₁₂alkyl, benzyl, or a monovalent acyl residue derived from an aliphatic, cycloaliphatic or aromatic monocarboxylic acid having up to 12 carbon atoms and one of the R₁₂ is hydrogen and the other is methyl.

More preferred is a compound of formula Ia, IIa or IIIa wherein



m is 1;

n is 1 ;

Y and Y' together form one of the bivalent groups -CH₂-C(R₁)(R₂)-CH(R₃)- wherein

R₁ is hydrogen, methyl or ethyl;


R₂ and R₃ are independently hydrogen, methyl ethyl, or COO-(C₁-C₁₂)alkyl; and one of the R₁₂ is hydrogen and the other is methyl.

Especially preferred is a compound of formula IIIa.


Specifically preferred compounds are listed in Tables 1, 2 and 3.

Table 1


1.) 2,6-Diethyl-4,4-dimethoxy-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




2.) 4,4-Diethoxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




3.) 2,6-Diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-4,4-dipropoxy-piperidine




4.) 4,4-Dibutoxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




5.) 2,6-Diethyl-4,4-diisobutoxy-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




6.) 2,6-Diethyl-2,3,6-trimethyl-4,4-bis-octyloxy-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




7.) 4,4-Bis-allyloxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




8.) 4,4-Bis-cyclohexyloxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




9.) 4,4-Bis-benzyloxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




10.) 7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




11.) 7,9-Diethyl-2,6,7,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




12.) 2,7,9-Triethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




13.) 7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-2-propyl-1,4-dioxo-8-aza-spiro[4.5]decane




14.) 2-Butyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




15.) 7,9-Diethyl-6,7,9-trimethyl-2-octyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




16.) 2-Decyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane



17.) 2-Dodecyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




18.) {7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-yl}-methanol




19.) Acetic acid 7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester


- 12 -




20.) Octadecanoic acid 7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester




21.) Benzoic acid 7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester




22.) 7,9-Diethyl-2-methoxymethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




23.) 2-Cyclohexyloxymethyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




24.) 2-Benzoyloxymethyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




25.) Octanedioic acid bis-{7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxa-8-aza-spiro[4.5]dec-2-ylmethyl} ester




26.) Terephthalic acid bis-{7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxa-8-aza-spiro[4.5]dec-2-ylmethyl} ester




27.) 1',4'-Bis-{7,9-diethyl-6,7,9-trimethyl-8-(1-(4-oxiranylmethoxy-phenyl)-ethoxy)-1,4-dioxa-8-aza-spiro[4.5]dec-2-ylmethyl}-oxybutane




28.) 7,9-Diethyl-2,2,6,7,9-pentamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




29.) 7,9-Diethyl-2,3,6,7,9-pentamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




30.) 4,4-(o-Phenylendioxy)-2,6-diethyl-2,3,6-trimethyl-1-[1'-(4'-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




31.) 4,4-(1',2'-cyclohexylendioxy)-2,6-diethyl-2,3,6-trimethyl-1-[1''-(4''-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




32.) 7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane-2,3-dicarboxylic acid dimethyl ester




33.) 8,10-Diethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




34.) 8,10-Diethyl-3,3,7,8,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




35.) 3,8,10-Triethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




36.) 3,3,8,10-Tetraethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




37.) 8,10-Diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-3-propyl-1,5-dioxo-9-aza-spiro[5.5]undecane




38.) 3-Butyl-3,8,10-triethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




39.) 2,4-Diethyl-1,2,4-trimethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,16-dioxo-3-azadispiro[5.2.5.2]hexadec-11-ene




40.) {8,10-Diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol




41.) {3,8,10-Triethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol




42.) 8,10-Diethyl-3-methoxymethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




43.) 3-Cyclohexyloxymethyl-8,10-diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




44.) 3-Benzyloxymethyl-8,10-diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




45.) Acetic acid 8,10-diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl ester




46.) Octanedioic acid bis-{8,10-diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} ester




47.) 1',6'-Bis-{3,8,10-triethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} -oxyhexane




48.) 8,10-Diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3-carboxylic acid methyl ester



49.) 8,10-Diethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3,3-dicarboxylic acid diethyl ester



50.) 3,3-Bis-(8,10-diethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane



51.) 2,4-Diethyl-1,2,4-trimethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,12-dioxo-3-aza-spiro[5.6]dodec-9-ene






Table 2


1.) 2,2-Diethyl-4,4-dimethoxy-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




2.) 4,4-Diethoxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




3.) 2,2-Diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-4,4-dipropoxy-piperidine




4.) 4,4-Dibutoxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




5.) 2,2-Diethyl-4,4-diisobutoxy-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




6.) 2,2-Diethyl-6,6-dimethyl-4,4-bis-octyloxy-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




7.) 4,4-Bis-allyloxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




8.) 4,4-Bis-cyclohexyloxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




9.) 4,4-Bis-benzyloxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




10.) 7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




11.) 7,7-Diethyl-2,9,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




12.) 2,7,7-Triethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




13.) 7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-2-propyl-1,4-dioxo-8-aza-spiro[4.5]decane




14.) 2-Butyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




15.) 7,7-Diethyl-9,9-dimethyl-2-octyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




16.) 2-Decyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




17.) 2-Dodecyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




18.) {7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-yl}-methanol




19.) Acetic acid 7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester




20.) Octadecanoic acid 7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester




21.) Benzoic acid 7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester




22.) 7,7-Diethyl-2-methoxymethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




23.) 2-Cyclohexyloxymethyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




24.) 2-Benzoyloxymethyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




25.) Octanedioic acid bis-{7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranymethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester




26.) Terephthalic acid bis-{7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranymethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester




27.) 1',4'-Bis-{7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranymethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl}-oxybutane




28.) 7,7-Diethyl-2,2,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxa-8-aza-spiro[4.5]decane




29.) 7,7-Diethyl-2,3,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxa-8-aza-spiro[4.5]decane




30.) 4,4-(o-Phenylendioxy)-2,2-diethyl-6,6-dimethyl-1-[1'-(4'-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




31.) 4,4-(1',2'-cyclohexylendioxy)-2,2-diethyl-6,6-dimethyl-1-[1''-(4''-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




32.) 7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxa-8-aza-spiro[4.5]decane-2,3-dicarboxylic acid dimethyl ester




33.) 8,8-Diethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




34.) 8,8-Diethyl-3,3,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




35.) 3,8,8-Triethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




36.) 3,3,8,8-Tetraethyl-10,10-dimethyl-9-[1-(4-oxiranylethoxy-phenyl)-ethoxy]-1,5-dioxaspiro[5.5]undecane




37.) 8,8-Diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-3-propyl-1,5-dioxa-9-aza-spiro[5.5]undecane




38.) 3-Butyl-3,8,8-triethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




39.) 2,2-Diethyl-4,4-dimethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,16-dioxo-3-azadispiro[5.2.5.2]hexadec-11-ene




40.) {8,8-Diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol




41.) {3,8,8-Triethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol




42.) 8,8-Diethyl-3-methoxymethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




43.) 3-Cyclohexyloxymethyl-8,8-diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




44.) 3-Benzyloxymethyl-8,8-diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




45.) Acetic acid 8,8-diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl ester




46.) Octanedioic acid bis-{8,8-diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} ester




47.) 1',6'-Bis-{3,8,8-triethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} -oxyhexane




48.) 8,8-Diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3-carboxylic acid methyl ester



49.) 8,8-Diethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3,3-dicarboxylic acid diethyl ester



50.) 3,3-Bis-[8,8-diethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza]-spiro[5.5]undecane



51.) 2,2-Diethyl-4,4-dimethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,12-dioxo-3-aza-spiro[5.6]dodec-9-ene






Table 3


1.) 4,4-Dimethoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




2.) 4,4-Diethoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




3.) 2,2,6,6-Tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-4,4-dipropoxy-piperidine




4.) 4,4-Dibutoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




5.) 4,4-Diisobutoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




6.) 2,2,6,6-Tetramethyl-4,4-bis-octyloxy-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




7.) 4,4-Bis-allyloxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




8.) 4,4-Bis-cyclohexyloxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




9.) 4,4-Bis-benzyloxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




10.) 7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxaspiro[4.5]decane




11.) 2,7,7,9,9-Pentamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




12.) 2-Ethyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




13.) 7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-2-propyl-1,4-dioxo-8-aza-spiro[4.5]decane




14.) 2-Butyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




15.) 7,7,9,9-Tetramethyl-2-octyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




16.) 2-Decyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




17.) 2-Dodecyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




18.) {7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-yl}-methanol




19.) Acetic acid 7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester




20.) Octadecanoic acid 7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester




21.) Benzoic acid 7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester




22.) 2-Methoxymethyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




23.) 2-Cyclohexyloxymethyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




24.) 2-Benzoyloxymethyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




25.) Octanedioic acid bis-{7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester




26.) Terephthalic acid bis-{7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester




27.) 1',4'-Bis-{7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl}-oxybutane




28.) 2,2,7,7,9,9-Hexamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




29.) 2,3,7,7,9,9-Hexamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane




30.) 4,4-(o-Phenylendioxy)-2,2,6,6-tetramethyl-1-[1'-(4'-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




31.) 4,4-(1',2'-cyclohexylendioxy)-2,2,6,6-tetramethyl-1-[1''-(4''-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




32.) 7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane-2,3-dicarboxylic acid dimethyl ester




33.) 8,8,10,10-Tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




34.) 3,3,8,8,10,10-Hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




35.) 3-Ethyl-3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




36.) 3,3-Diethyl-8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




37.) 3,8,8,10,10-Pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-3-propyl-1,5-dioxo-9-aza-spiro[5.5]undecane




38.) 3-Butyl-3-ethyl-8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




39.) 2,2,4,4-Tetramethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,16-dioxa-3-aza-dispiro[5.2.5.2]hexadec-11-ene




40.) {3,8,8,10,10-Pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl}-methanol




41.) {3-Ethyl-8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl}-methanol




42.) 3-Methoxymethyl-3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undecane




43.) 3-Cyclohexyloxymethyl-3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undecane




- 44.) 3-Benzyloxymethyl-3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




- 45.) Acetic acid 3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl ester




- 46.) Octanedioic acid bis-{3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} ester




- 47.) 1',6'-Bis-{8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} -oxyhexane




- 48.) 3,8,8,10,10-Pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3-carboxylic acid methyl ester




49.) 8,8,10,10-Tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3,3-dicarboxylic acid diethyl ester



50.) 3,3-Bis-{8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




51.) 2,2,4,4-Tetramethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,12-dioxo-3-aza-spiro[5.6]dodec-9-ene




Particularly preferred are the following compounds:


4,4-Dibutoxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxa-8-aza-spiro[4.5]decane




8,10-Diethyl-3,3,7,8,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undecane




{8,10-Diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl}-methanol




{3,8,10-Triethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl}-methanol




4,4-Dibutoxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxa-8-aza-spiro[4.5]decane




8,8-Diethyl-3,3,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undecane




{8,8-Diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl}-methanol




{3,8,8-Triethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl}-methanol




4,4-Dibutoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine




7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane



3,3,8,8,10,10-Hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




Most preferred is 3,3,8,8,10,10-Hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane




A further subject of the invention is a polymerizable composition, comprising

- a) at least one ethylenically unsaturated monomer or oligomer, and
- b) a compound of formula Ia, IIa or IIIa

- 44 -



wherein

D is a group  or a group C(O)-R₁₃;

R₁₃ is phenyl or C₁-C₁₈alkyl;


m is 1, 2 or 3;

n is 1 or 2;

if n is 1

Y and Y' are independently C₁-C₁₂alkyl, C₃-C₁₂alkenyl, C₃-C₁₂alkinyl, C₅-C₈cycloalkyl, phenyl, naphthyl, C₇-C₉phenylalkyl; or

Y and Y' together form one of the bivalent groups -C(R₁)(R₂)-CH(R₃)-, CH(R₁)-CH₂-C(R₂)(R₃)-, -CH(R₂)-CH₂-C(R₁)(R₃)-, -CH₂-C(R₁)(R₂)-CH(R₃)-, o-phenylene, 1,2-cyclohexyliden,

-CH₂-CH=CH-CH₂- or ; wherein


R₁ is hydrogen, C₁-C₁₂alkyl, COOH, COO-(C₁-C₁₂)alkyl or CH₂OR₄;

R₂ and R₃ are independently hydrogen, methyl ethyl, COOH or COO-(C₁-C₁₂)alkyl;

R₄ is hydrogen, C₁-C₁₈alkyl, benzyl, or a monovalent acyl residue derived from an aliphatic, cycloaliphatic or aromatic monocarboxylic acid having up to 18 carbon atoms;

if n is 2

Y and Y' together form one of the tetravalent groups



Q is a bisacyl residue which is derived from a C_2 - C_{12} dicarboxylic acid or C_1 - C_{12} alkylene;
 Z is C_1 - C_{12} alkylene;
 the R_{12} are independently of each other H or CH_3 .

Definitions and preferences have already been given above for the compounds. They apply also for the composition.

The monomers suitable for use in the present invention may be water-soluble or water-insoluble. Water soluble monomers contain typically a salt of a carboxylic acid group. Water insoluble monomers are typically free of acid and phenolic groups.

Typical metal atoms are Na, K or Li.

Typical monoethylenically unsaturated monomers free of carboxylic acid and phenolic groups which are suitable for this invention include the alkyl esters of acrylic or methacrylic acids such as methyl acrylate, ethyl acrylate, butyl acrylate, methyl methacrylate, ethyl methacrylate, butyl methacrylate and isobutyl methacrylate; the hydroxyalkyl esters of acrylic or methacrylic acids, such as hydroxyethyl acrylate, hydroxypropyl acrylate, hydroxyethyl methacrylate, and hydroxypropyl methacrylate; acrylamide, methacrylamide, N-tertiary butylacrylamide, N-methylacrylamide, N,N-dimethylacrylamide; acrylonitrile, methacrylonitrile, allyl alcohol, dimethylaminoethyl acrylate, dimethylaminoethyl methacrylate,

phosphoethyl methacrylate, N-vinylpyrrolidone, N-vinylformamide, N-vinylimidazole, vinyl acetate, conjugated dienes such as butadiene or isoprene, styrene, styrenesulfonic acid salts, vinylsulfonic acid salts and 2-acrylamido-2-methylpropane-sulfonic acid salts and acryloil chloride.

Preferred ethylenically unsaturated monomers or oligomers are selected from the group consisting of styrene, substituted styrene, conjugated dienes, acrolein, vinyl acetate, (alkyl)acrylic acid anhydrides, (alkyl)acrylic acid salts, (alkyl)acrylic esters or (alkyl)acrylamides.

Particularly preferred ethylenically unsaturated monomers are styrene, α -methyl styrene, p-methyl styrene, butadiene, methylacrylate, ethylacrylate, propylacrylate, n-butyl acrylate, tert.-butyl acrylate and acrylonitril.

In a most preferred composition the ethylenically unsaturated monomer is styrene.

Preferred acrylates are methylacrylate, ethylacrylate, butylacrylate, isobutylacrylate, tert. butylacrylate, hydroxyethylacrylate, hydroxypropylacrylate, dimethylaminoethylacrylate, glycidylacrylates, methyl(meth)acrylate, ethyl(meth)acrylate, butyl(meth)acrylate, hydroxyethyl(meth)acrylate, hydroxypropyl(meth)acrylate, dimethylaminoethyl(meth)acrylate, glycidyl(meth)acrylates, acrylonitrile, acrylamide or methacrylamide.

Examples for C_8 - C_{16} ethylenically unsaturated phenolics, which may also be used as comonomers include 4-hydroxy styrene, 4-hydroxy- α -methyl styrene, and 2,6-ditert. butyl, 4-vinyl phenol.

Another class of carboxylic acid monomers suitable for use as comonomers in this invention are the alkali metal and ammonium salts of C_4 - C_6 -ethylenically unsaturated dicarboxylic acids. Suitable examples include maleic acid, maleic anhydride, itaconic acid, mesaconic acid, fumaric acid and citraconic acid. Maleic anhydride (and itaconic acid are) is the preferred monoethylenically unsaturated dicarboxylic acid monomer(s).

The acid monomers suitable for use in this invention are in the form of the alkali metal salts or ammonium salts of the acid.


The polymerizable composition of the present invention may additionally comprise a solvent selected from the group consisting of water, alcohols, esters, ethers, ketones, amides, sulfoxides, hydrocarbons and halogenated hydrocarbons.

The invention also relates to a free radical polymerization process and polymers obtained thereby, which process overcomes many of the problems and disadvantages of the afore mentioned prior art processes.

Preferably the initiator compound is present in an amount of from 0.01 mol-% to 20 mol-%, more preferably in an amount of from 0.01 mol-% to 10 mol-% and most preferred in an amount of from 0.05 mol-% to 10 mol-% based on the monomer or monomer mixture.

When monomer mixtures are used mol-% is calculated on the average molecular weight of the mixture.

Another subject of the present invention is a process for preparing an oligomer, a cooligomer, a polymer or a copolymer (block or random) by free radical polymerization of at least one ethylenically unsaturated monomer or oligomer, which comprises (co)polymerizing the monomer or monomers/oligomers in the presence of an initiator compound of formula Ia, IIa or IIIa under reaction conditions capable of effecting scission of the O-C bond to form two

free radicals, the radical  being capable of initiating polymerization.

Preferably the scission of the O-C bond is effected by heating and takes place at a temperature of between 50°C and 160°C.

Preferred initiators and ethylenically unsaturated monomers have already been mentioned above.

Polydispersity (PD) of the polymers prepared by the present invention is preferably between 1.0 and 2.0, more preferably between 1.1 and 1.8 and most preferably between 1.1 and 1.6.

The process may be carried out in the presence of an organic solvent or in the presence of water or in mixtures of organic solvents and water. Additional cosolvents or surfactants, such as glycols or ammonium salts of fatty acids, may be present. Other suitable cosolvents are described hereinafter.

Preferred processes use as little solvents as possible. In the reaction mixture it is preferred to use more than 30% by weight of monomer and initiator, particularly preferably more than 50% and most preferably more than 80%.

If organic solvents are used, suitable solvents or mixtures of solvents are typically pure alkanes (hexane, heptane, octane, isooctane), hydrocarbons (benzene, toluene, xylene), halogenated hydrocarbons (chlorobenzene), alkanols (methanol, ethanol, ethylene glycol, ethylene glycol monomethyl ether), esters (ethyl acetate, propyl, butyl or hexyl acetate) and ethers (diethyl ether, dibutyl ether, ethylene glycol dimethyl ether), or mixtures thereof.

The aqueous polymerization reactions can be supplemented with a water-miscible or hydrophilic cosolvent to help ensure that the reaction mixture remains a homogeneous single phase throughout the monomer conversion. Any water-soluble or water-miscible cosolvent may be used, as long as the aqueous solvent medium is effective in providing a solvent system which prevents precipitation or phase separation of the reactants or polymer products until after all polymerization reactions have been completed. Exemplary cosolvents useful in the present invention may be selected from the group consisting of aliphatic alcohols, glycols, ethers, glycol ethers, pyrrolidines, N-alkyl pyrrolidinones, N-alkyl pyrrolidones, polyethylene glycols, polypropylene glycols, amides, carboxylic acids and salts thereof, esters, organosulfides, sulfoxides, sulfones, alcohol derivatives, hydroxyether derivatives such as butyl carbitol or cellosolve, amino alcohols, ketones, and the like, as well as derivatives thereof and mixtures thereof. Specific examples include methanol, ethanol, propanol, dioxane, ethylene glycol, propylene glycol, diethylene glycol, glycerol, dipropylene glycol, tetrahydrofuran, and other water-soluble or water-miscible materials, and mixtures thereof. When mixtures of water and water-soluble or water-miscible organic liquids are selected as the aqueous reaction media, the water to cosolvent weight ratio is typically in the range of about 100:0 to about 10:90.

When monomer mixtures or monomer/oligomer mixtures are used, the calculation of mol-% is based on an average molecular weight of the mixture.

Hydrophilic monomers, polymers and copolymers of the present invention can be separated from one another or from the polymerization reaction mixture by, for example, changing the pH of the reaction media and by other well known conventional separation techniques.

The polymerization temperature may range from about 50°C to about 180°C, preferably from about 80°C to about 150°C. At temperatures above about 180°C, the controlled conversion of the monomer into polymer decreases, and uncertain and undesirable by-products like thermally initiated polymer are formed or destruction of the polymerization regulator may occur. Frequently, these by-products discolor the polymer mixture and a purification step may be required to remove them, or they may be intractable.

Therefore high reactivity of the present initiators which are already active at relatively low temperatures leads to short reaction times. The resulting polymers are usually colourless and they can be used in most cases without any further purification step. This is an important advantage when industrial scale-up is considered.

After the polymerizing step is complete, the formed (co)polymer obtained is isolated. The isolating step of the present process is conducted by known procedures, e.g. by distilling off the unreacted monomer or by precipitation in a suitable nonsolvent, filtering the precipitated polymer followed by washing and drying the polymer.

Furthermore, block copolymers of this invention, wherein the blocks alternate between polar monomers and non-polar monomers, are useful in many applications as amphiphilic surfactants or dispersants for preparing highly uniform polymer blends.

The (co)polymers of the present invention may have a number average molecular weight from 1 000 to 400 000 g/mol, preferably from 2 000 to 250 000 g/mol and, more preferably, from 2 000 to 200 000 g/mol. When produced in bulk, the number average molecular weight may be up to 500 000 (with the same minimum weights as mentioned above). The number average molecular weight may be determined by size exclusion chromatography (SEC), gel permeation chromatography (GPC), matrix assisted laser desorption/ionization mass spectrometry (MALDI-MS) or, if the initiator carries a group which can be easily distinguished from the monomer(s), by NMR spectroscopy or other conventional methods.

Thus, the present invention also encompasses in the synthesis novel block, multi-block, star, gradient, random, hyperbranched and dendritic copolymers, as well as graft or copolymers.

The polymers prepared by the present invention are useful for example in following applications:

adhesives, detergents, dispersants, emulsifiers, surfactants, defoamers, adhesion promoters, corrosion inhibitors, viscosity improvers, lubricants, rheology modifiers, impact modifiers, thickeners, crosslinkers, paper treatment, water treatment, electronic materials, paints, coatings, photography, ink materials, imaging materials, superabsorbants, cosmetics, hair products, preservatives, biocide materials or modifiers for asphalt, leather, textiles, ceramics and wood.

Because the present polymerization is a "living" polymerization, it can be started and stopped practically at will. Furthermore, the polymer product retains the functional alkoxyamine group allowing a continuation of the polymerization in a living matter. Thus, in one embodiment of this invention, once the first monomer is consumed in the initial polymerizing step a second monomer can then be added to form a second block on the growing polymer chain in a second polymerization step. Therefore it is possible to carry out additional polymerizations with the same or different monomer(s) to prepare multi-block copolymers.


Furthermore, since this is a radical polymerization, blocks can be prepared in essentially any order. One is not necessarily restricted to preparing block copolymers where the sequential polymerizing steps must flow from the least stabilized polymer intermediate to the most stabilized polymer intermediate, such as is the case in ionic polymerization. Thus it is possible to prepare a multi-block copolymer in which a polyacrylonitrile or a poly(meth)acrylate block is prepared first, then a styrene or butadiene block is attached thereto, and so on.

Furthermore, there is no linking group required for joining the different blocks of the present block copolymer. One can simply add successive monomers to form successive blocks.


A plurality of specifically designed polymers and copolymers are accessible by the present invention, such as star and graft (co)polymers as described, inter alia, by C. J. Hawker in *Angew. Chemie*, 1995, 107, pages 1623-1627, dendrimers as described by K. Matyaszewski et al. in *Macromolecules* 1996, Vol 29, No. 12, pages 4167-4171, graft (co)polymers as described by C. J. Hawker et al. in *Macromol. Chem. Phys.* 198, 155-166(1997), random copolymers as described by C. J. Hawker in *Macromolecules* 1996, 29, 2686-2688, or

diblock and triblock copolymers as described by N. A. Listigovers in *Macromolecules* 1996, 29, 8992-8993.


Still further subjects of the invention are a polymer or oligomer, containing at least one

initiator group  and at least one oxyamine group of formula Ib,


Ib or IIIb



(Ib)



(IIb)




(IIIb)

wherein Y and Y' are as defined above, obtainable by the process described above; and the use of a compound of formula Ia, IIa or IIIa for polymerizing ethylenically unsaturated monomers.


Also subject of the invention is the use of a compound of formula Ia, IIa or IIIa for terminating the anionic polymerization of a diene or vinyl monomer.

When the compounds are used for such termination reactions they are usually used in an equimolar amount or in excess to the initiating base, such as for example sec. butyl-lithium.


The preparation of the compounds of the present invention is carried out according to known reaction steps. A general method for the preparation of the compounds of formula Ia, IIa, and IIIa starts from the 4-oxo compounds Xa or XIa which are described in GB 2335190 or from XIIa which is a known compound described for example in DE 2352127.




These starting compounds are reacted for example with suitable monoalcohols, diols or tetrafunctional alcohols to form intermediates of formula Xb, XIb or XIIb wherein Y, Y' and n are as defined above. Such ketalization reactions are well known in the art and the corresponding compounds are mostly known. The reaction is for example described in US 3790525, US 3899464, US 4007158 and US 4105626.



The compounds of formula Xb, XIb and XIIb are oxidized according to standard procedures to the corresponding nitroxides of formula Xc, XIc and XIIc, as for example described in GB 2335190 or WO 99/46261.



The nitroxides are then reacted with a compound of formula




wherein R_{12} and m are as defined above to obtain a compound of

formula Ia, IIa or IIIa.

This coupling reaction is also described for example in GB 2335190 or in WO 99/46261.




Preferably the coupling reaction is carried out in the presence of a Cu(II) salt according to the method described in International Application No. PCT/EP01/05668.

Alternatively the nitroxides of formula Xc, XIc or XIIc can be reacted with a compound of



formula . The reaction products are subsequently hydrolyzed

to form a compound of formula Xd, XId or XIId.



These compounds are novel and consequently are also subject of the present invention.


The above given definitions and preferences apply also for the compounds of formula Xd, XId and XIId.

The compounds of formula Xd, Xld and Xlld can be reacted with epichlorohydrine and compounds according to formula Ia, IIa or IIIa are obtained.

The following examples illustrate the invention.


Preparation of an intermediate according to formula Xlld.

Preparation of acetic acid 4-[1-(3,3,8,8,10,10-hexamethyl-1,5-dioxo-9-aza-spiro[5.5]undec-9-yloxy)-ethyl]-phenyl ester



A mixture of 25,6 g 3,3,8,8,10,10-hexamethyl-1,5-dioxo-9-aza-spiro[5.5]undecan-9-oxyl (prepared according to EP 574666A1) and 82,1 g acetic acid 4-ethyl-phenyl ester are heated to 50° C with stirring and 0,68 ml of an ethanolic solution containing 0,13 g copper(II)chloride is added. The temperature is raised to 65°C and 19,4 g of an aqueous solution of butylhydroperoxide in water (70%) are dropwise added. The reaction mixture is allowed to further react for 22h at 65° - 70°C and subsequently cooled to room temperature. Excess tert.-butylhydroperoxide is removed by dropwise adding 4ml of an aqueous sodium pyrosulfite solution (20%). To the reaction mixture 50ml acetic acid ethylester are added and the organic and aqueous phase are separated. The organic phase is washed with a saturated NaCl solution. After drying with sodium sulfate and evaporation of the solvent an oil is obtained, from which excess acetic acid 4-ethyl-phenyl ester is removed by distillation (100°C/0,025 mbar). The residue is dissolved in methanol/hexane (4/1 by volume) on heating to reflux. After cooling to 0°C the precipitate is filtered off. After recrystallization from acetone white crystals are obtained having a melting point of 124 - 125° C.


Preparation of 4-[1-(3,3,8,8,10,10-Hexamethyl-1,5-dioxo-9-aza-spiro[5.5]undec-9-yloxy)-ethyl]-phenol



A mixture of 8 g acetic acid 4-[1-(3,3,8,8,10,10-hexamethyl-1,5-dioxo-9-aza-spiro[5.5]undec-9-yloxy)-ethyl]-phenyl ester and 3,9 g potassium carbonate in 60 ml methanol is stirred for one hour at room temperature. The mixture is cooled to 0°C and neutralized by adding 60 ml of 0,5 M hydrochloric acid. The white suspension is diluted with water (60 ml) and filtered through a buchner funnel. The residue is washed with water and dried in a vacuum oven at 50°C. A white solid having a melting point of 133 – 134°C is obtained.


Preparation of compounds according to formulae Ia, IIa and IIIa

Example A1: Preparation of 7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decan



A mixture of 50 g 7,7,9,9-tetramethyl-1,4-dioxo-8-aza-spiro[4.5]decan-8-oxyl (prepared according to EP 574666A1) and 124,75 g 2-(4-ethyl-phenoxy-methyl)-oxiran are heated to 60° C with stirring and a solution of 0,32 g copper(II)chloride in 1,6 ml ethanol is added. 45 g of an aqueous solution of butylhydroperoxide in water (70%) is dropwise added. The reaction mixture is allowed to further react for 16h at 60° C and subsequently cooled to room temperature. Excess tert.-butylhydroperoxide is removed by dropwise adding 15ml of an aqueous sodium pyrosulfite solution. To the reaction mixture 100ml acetic acid ethylester are added and the organic and aqueous phase are separated. The organic phase is washed twice with 200 ml of a saturated NaCl solution. After drying with sodium sulfate and evaporation of the solvent an oil is obtained, from which excess 2-(4-ethyl-phenoxy-methyl)-oxiran is removed by distillation (100°C/0,005 mbar). The residue is dissolved in hexane filtered over aluminium oxide and the solvent is again evaporated. After recrystallization from hexane white crystals are obtained having a melting point of 73.5-74.2° C.





Example A2: Preparation of 3,3,8,8,10,10-hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecan







The title compound is prepared in analogy to example A1 from 3,3,8,8,10,10-hexamethyl-1,5-dioxo-9-aza-spiro[5.5]undecan-9-oxyl (prepared according to EP 574666A1). White crystals are obtained.

Elemental analysis: calculated: 69,25% C; 9,07% H; 3,23% N; found: 68,86% C; 9,05% H; 3,18% N.

The following compounds are prepared according to example A1, starting from the corresponding nitroxide.

No.	Struktur	Phys. Daten	NMR Data
A3			¹ H-NMR (400 MHz; δ in ppm; CDCl ₃): 0,63 (broad s, 3 H); 1,0 – 1,95 (m, 16 H); 1,45-1,47 (d, 3 H); 2,73-2,75 (m, 1 H); 2,88-2,9 (m, 1 H); 3,2-3,55 (m, 2 H); 3,85-4,3 (m, 4 H); 4,72-4,77 (q, 1 H); 6,84-6,87 and 7,22-7,25 (aromatic H, 4 H).
A4		m.p. 52 - 58,5°C	
A5		m.p. 118,5 - 121 °C	
A6		m.p. 88,5 - 93°C	


No.	Struktur	Phys. Daten	NMR Data
A7		m.p. 64,5 - 67°C	
A8		m.p. 102 - 109°C	
A9		m.p. 56 - 59°C	
A10			¹ H-NMR (400 MHz; δ in ppm; CDCl_3): 0,55-1,65 (m, 31 H); 1,95-2,25 (m, 2 H); 2,74-2,76 (m, 1 H); 2,89-2,91 (m, 1 H); 3,35 (m, 1 H); 3,5 (m, 4 H); 3,94-3,98 (m, 1 H); 4,17-4,21 (m, 1 H); 4,71-4,76 (q, 1 H); 6,84-6,87 and 7,22-7,25 (aromatic H, 4 H).
A11		m.p. 119,5 - 128°C	
A12		m.p. 116 - 121,5°C	
A13		m.p. 66,5 - 68,5°C	

No.	Struktur	Phys. Daten	NMR Data
A14		m.p. 42 – 55°C	
A15			¹ H-NMR (400 MHz; δ in ppm; CDCl ₃): 0,55-2,4 (m, 39 H); 2,74-2,76 (m, 1 H); 2,88-2,91 (m, 1 H); 3,3-3,7 (m, 9 H); 3,94-3,98 (m, 1 H); 4,17-4,21 (m, 1 H); 4,71-4,76 (q, 1 H); 6,84-6,87 and 7,22-7,25 (aromatic H, 4 H).
A16		m.p. 82 – 88°C	¹ H-NMR (400 MHz; δ in ppm; CDCl ₃): 0,6-1,65 (m, 23 H); 2-2,25 (m, 2 H); 2,75-2,78 (m, 1 H); 2,89-2,91 (m, 1 H); 3,3-3,4 (m, 1 H); 3,45 (s, 4 H); 3,9-4,0 (m, 1 H); 4,15-4,25 (m, 1 H); 4,7-4,77 (q, 1 H); 6,75-7,25 (aromatic H, 4 H).
A17			¹ H-NMR (300 MHz; δ in ppm; CDCl ₃): 0,7-1,7 (m, 17 H); 0,95 (s, 6 H); 2-2,25 (m, 2 H); 2,74-2,79 (m, 1 H); 2,87-2,9 (m, 1 H); 3,3-3,4 (m, 1 H); 3,46 (s, 4 H); 3,9-4,05 (m, 1 H); 4,15-4,25 (m, 1 H); 5,2-5,3 (q, 1 H); 6,8-7,5 (aromatic H, 4 H).

Example A18: {4-[1-(3,3,8,8,10,10-Hexamethyl-1,5-dioxa-9-aza-spiro[5.5]undec-9-yloxy)-ethyl]-phenyl}-phenyl-methanone

A mixture of 50 g 3,3,8,8,10,10-hexamethyl-1,5-dioxa-9-aza-spiro[5.5]undecan-9-oxyl (CAS 98254-32-1) and 41 g (4-Ethyl-phenyl)-phenyl-methanone (preparation by Friedel-Crafts acylation of 4-ethylbenzene with benzoylchloride) is heated to 60°C and a solution of 0,26 g copper(II)chloride in 1,3 ml ethanol is added. 53,7 g of a 70% aqueous solution of tert-butylhydroperoxide in water are added dropwise. The reaction mixture is allowed to further react for 28 h and subsequently cooled to room temperature. Excess tert-butylhydroperoxide

is then removed by dropwise adding an aqueous solution of sodium pyrosulfite. To the reaction mixture 100 ml of ethyl acetate are added and the organic phase is separated from the aqueous phase. The organic phase is washed twice with water (200 ml) and the solvent evaporated. The residue is purified chromatographically on silica gel with hexane/ethyl acetate (7:3 by volume) as the eluente. After recrystallization from pentane/ethanol (5:3 by volume) white crystals of a compound of formula




are obtained having a melting range of 104 – 117°C.

¹H-NMR (300 MHz; δ in ppm; CDCl₃): 0,7 (s broad, 3 H); 0,94 (s broad, 6 H); 1,18 (s broad, 3 H); 1,33 (s broad, 6 H); 1,51-1,53 (d, 3 H); 1,4-1,65 (m, 2 H); 2-2,25 (m, 2 H); 3,46 (s broad, 4 H); 4,84-4,91 (q, 1 H); 7,4-7,9 (aromatic H, 9 H).



Example A19: 8,8-Diethyl-3,3,10,10-tetramethyl-9-[1-(4-oxiranymethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane

To a stirred mixture of 25,6 g 8,8-diethyl-3,3,10,10-tetramethyl-1,5-dioxo-9-aza-spiro[5.5]undecan-9-oxyl and 80,2 g 2-(4-ethyl-phenoxy-methyl)-oxirane at 50°C is added a solution of 0,12 g copper(II)chloride in 0,6 ml ethanol. The temperature of the reaction mixture is increased to 70°C and 11,6 g of a 70% aqueous solution of tert-butylhydroperoxide in water are added dropwise. The reaction mixture is allowed to further react for 6 h at 70°C and subsequently cooled to room temperature. Excess tert-butylhydroperoxide is removed by dropwise adding an aqueous solution of sodium pyrosulfite (2 ml). To the reaction mixture 50 ml of ethyl acetate and 50 ml 10% aqueous solution of sodium chloride are added. The mixture is filtered through celite and the organic phase is separated. The organic phase is washed three times with 10% aqueous solution of sodium chloride (100 ml) and dried over sodium sulfate. After evaporation of the solvent an oil is obtained, from which excess 2-(4-ethyl-phenoxy-methyl)-oxirane is removed by distillation (80°C, 0,025 mbar). A highly viscous residue is obtained which crystallises on standing at room temperature. After recrystallization twice from methanol white crystals of

- 60 -

the compound of formula  are obtained having a melting point of 82 - 85°C.

According to the preparation of 8,8-Diethyl-3,3,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane, the following compounds are synthesized in analogy:

No.	Structure	NMR-data
A20		¹ H-NMR (400 MHz; δ in ppm; CDCl ₃): 0,4-2,5 (m, 27 H); 2,75-2,76 (m, 1 H); 2,89-2,91 (m, 1 H); 3,34-3,36 (m, 1 H); 3,4-3,55 (m, 2 H); 3,7-3,85 (m, 2 H); 3,94-3,98 (m, 1 H); 4,18-4,21 (m, 1 H); 4,63-4,68 (q, 1 H); 6,84-6,86 and 7,19-7,21 (aromatic H, 4 H).
A21		¹ H-NMR (400 MHz; δ in ppm; CDCl ₃): 0,5-2,2 (m, 23 H); 2,74-2,76 (m, 1 H); 2,89-2,91 (m, 1 H); 3,33-3,37 (m, 1 H); 3,7-4,05 (m, 5 H); 4,18-4,21 (m, 1 H); 4,64-4,69 (q, 1 H); 6,84-6,87 and 7,19-7,21 (aromatic H, 4 H).


Example A22: 8,10-diethyl-3,3,7,8,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane

To a stirred mixture of 59,7 g 8,10-diethyl-3,3,7,8,10-pentamethyl-1,5-dioxo-9-aza-spiro[5.5]undecan-9-oxyl and 178,2 g 2-(4-ethyl-phenoxy-methyl)-oxirane a solution of 0,27 g copper(II)chloride in 1,35 ml ethanol is added at about 60°C. Then 38,7 g of a 70% aqueous

solution of tert-butylhydroperoxide in water are added dropwise. An exothermic reaction started and the temperature is kept at 70°C. The reaction mixture is allowed to further react for 24 h at 70°C and subsequently cooled to room temperature. The reaction mixture is diluted with 100 ml of ethyl acetate. Excess tert-butylhydroperoxide is removed by dropwise adding an aqueous solution of sodium pyrosulfite (70 ml) below 20°C. The organic phase is separated, washed twice with 10% aqueous solution of sodium chloride (100 ml) and dried over sodium sulfate. After evaporation of the solvent an oil is obtained, from which excess 2-(4-ethyl-phenoxy)methyl-oxirane is removed by distillation (80°C, 0,025 mbar). A highly viscous resin

is obtained which is dissolved in methanol (20 ml) and cooled to about -18°C. White crystals precipitate and are collected by filtration having a melting point of 141 – 147°C. The

compound has the following structural formula



According to the preparation of 8,10-Diethyl-3,3,7,8,10-pentamethyl-9-[1-(4-oxiranylmethoxyphenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane, the following compound is synthesized in analogy:

No.	Structure	
A23		¹ H-NMR (400 MHz; δ in ppm; CDCl ₃): 0,5 – 2,3 (m, 25 H); 2,75 – 2,76 (m, 1 H); 2,89 – 2,91 (m, 1 H); 3,34 – 3,36 (m, 1 H); 3,7 – 4,1 (m, 5 H); 4,18 – 4,21 (m, 1 H); 4,66 – 4,72 (m, 1 H); 6,83 – 6,86 and 7,18 – 7,21 (aromatic H, 4 H).

Polymerization experiments with styrene

Example B1:

Styrene is distilled under reduced pressure prior to use. In a dry, argon-purged Schlenk tube, the amounts of nitroxyl ether given in Table 1 are dissolved in 50 ml styrene. The solution is

degassed in three consecutive freeze-thaw-cycles and then purged with argon. The stirred solution is then immersed in an oil bath and polymerized at the given temperature for 6 hours. After polymerization, residual monomer is removed under vacuum at 60°C and the polymer is dried at 60°C in vacuo until constant weight is achieved.

Molecular weight and molecular weight distributions are determined by size exclusion chromatography (SEC) on a HP 1090 liquid chromatograph (software: winGPC / Polymer Standard Services, Mainz, Germany) using THF as eluent and a column combination calibrated with narrow polystyrene standards (Polymer Laboratories). The results are given in Table 1.

NOR of example A2




Table 1

NOR	Temp [° C]	mol% NOR	Styrene Conversion (%)	M _n (calc.)	M _n (GPC)	M _w (GPC)	M _w /M _n (GPC)
Example A2	120	1 mol%	40	4700	4300	5200	1.24
Example A2	120	0.1 mol%	44	46000	28400	36900	1.30
Example A2	130	1 mol%	48	5300	4800	5800	1.21
Example A2	130	0.1 mol%	61	64500	37200	49500	1.33

Following the general description of example B1 further polymerizations in styrene were carried out and the following results obtained.

Example B2

NOR of example A1




Table 2

Exp. #	Temp. (°C)	Mol% NOR	Yield (%)	M _n (calc.)	M _n	M _w	M _w /M _n
1	120	1	20	2400	1800	2200	1.25
2	120	0.1	41	43400	23300	37000	1.59
3	130	1	41	4700	3500	4300	1.23
4	130	0.1	55	58000	30900	42900	1.39

Example B3

NOR of example A6




Table 3

Exp. #	Temp. (°C)	Mol% NOR	Yield (%)	M _n (calc.)	M _n	M _w	M _w /M _n
1	120	1	41	4600	3700	4500	1.22
2	120	0.1	46	47900	32500	41000	1.26
3	130	1	46	5200	3900	4700	1.18
4	130	0.1	61	63800	38600	50200	1.30

Example B4

NOR of example A5




Table 4

Exp. #	Temp. (°C)	Mol% NOR	Yield (%)	M _n (calc.)	M _n	M _w	M _w /M _n
1	120	1	39	4500	3500	4300	1.21
2	120	0.1	51	53500	34800	42700	1.23
3	130	1	52	5800	4400	5500	1.24
4	130	0.1	59	61800	31400	44200	1.41

Example B5

NOR of example A4




Table 5

Exp. #	Temp. (°C)	Mol% NOR	Yield (%)	M _n (calc.)	M _n	M _w	M _w /M _n
1	120	1	26	3100	2600	3200	1.23
2	120	0.1	37	39000	27700	35400	1.28
3	130	1	51	5700	4800	6000	1.24
4	130	0.1	57	59600	35400	47800	1.35

Example B6

NOR of example A9




Table 6

Exp. #	Temp. (°C)	Mol% NOR	Yield (%)	M _n (calc.)	M _n	M _w	M _w /M _n
1	120	1	26	3100	2700	3300	1.26
2	120	0.1	38	40400	28100	35700	1.27
3	130	1	54	6100	5000	6000	1.20
4	130	0.1	60	62600	37600	49500	1.32

Polymerization with n-BuAExample B7

n-Butylacrylate is distilled under reduced pressure prior to use. In a dry, argon-purged Schlenk tube, the amounts of nitroxyl ether given in Table A are dissolved in 62.5 ml n-butylacrylate. The solution is degassed in three consecutive freeze-thaw-cycles and then purged with argon. The stirred solution is then immersed in an oil bath and polymerized at

130°C for 6 hours. After polymerization, residual monomer is removed under vacuum at 30°C and the polymer is dried at 30°C in vacuum until constant weight is achieved.

Molecular weight and molecular weight distributions are determined by size exclusion chromatography (SEC) on a HP 1090 liquid chromatograph (software: winGPC / Polymer Standard Services, Mainz, Germany) using THF as eluent and a column combination calibrated with narrow polystyrene standards (Polymer Laboratories). The results are given in Table 7.

Table 7

NOR of	Temp. [°C]	mol% NOR	n-BuA Conv. [%]	Mn (calc.)	Mn (GPC)	Mw (GPC)	Mw/Mn (GPC)
example A20	130	1 mol%	45	6217	6761	8095	1.20
example A20	130	0.1 mol%	41	52856	45900	56710	1.24
example A19	130	1 mol%	54	7373	7046	8574	1.22
example A19	130	0.1 mol%	35	45731	39070	47090	1.21
example A22	130	1 mol%	61	8233	8137	9762	1.20
example A22	130	0.1 mol%	60	77326	57120	72870	1.28

Example B8: Anionic polymerization and termination of isoprene with the compound of example A2

To 10.2 g (0.15 mol) isoprene dissolved in 50 ml dry toluene in a dried ampule with teflon valve equipped with a magnetic stir bar are added in a dry argon atmosphere $3,34 \times 10^{-3}$ mol sec.-butyllithium (1.3 mol/L solution in cyclohexane, Fluka) and stirred for 18 hours at room temperature to allow polymerization. Subsequently a sample of the resulting prepolymer is drawn via syringe, dried at room temperature in vacuo and submitted to GPC. To the residual, slightly yellow polyisoprene solution is slowly added a calculated amount of the compound of example A2 (1.2 and 1.5 fold molar excess with respect to the initial molar amount of sec.-butyllithium used) (dissolved in toluene and degassed) via syringe. The mixture is allowed to react for another 6 hours at room temperature. Subsequently the termination reaction is quenched adding a few ml of degassed methanol. Volatiles are removed in vacuo and the resulting polyisoprene is obtained as a slight yellow rubber after

drying at room temperature in vacuo until constant weight is achieved. Molecular weights are determined by GPC on a HP 1090 equipped with a RI and DAAD (set at 254 nm) detector with THF as eluent (1 ml/min), using PS standards for calibration.

Ex.	terminating agent of example A2	conversion isoprene (%)	M _n (calc.) (prepolymer)	M _n (GPC) (RI detection) prepolymer/polymer after reaction		M _w /M _n prepolymer/polymer after reaction	
1	1.2 x excess	93	2800	2700*	3500**	1.23*	1.16**
2	1.5 x excess	81	2400	2600*	3300**	1.20*	1.14**

*polymer before termination with the compound of example A2

**polymer after termination with the compound of example A2


Reinitiation of terminated polyisoprene with styrene (terminating agent is compound of example A2)

In a dried, argon purged Schlenk tube equipped with an argon inlet and a magnetic stir bar, 5 g of samples 1 and 2 above are dissolved in 25 g of freshly distilled styrene each. The solutions are degassed by two consecutive freeze-thaw cycles and immersed in an oil bath at 120°C to allow polymerization. After 6 hours, residual monomer is removed in vacuo and the resulting polymer is dried in vacuo at 70°C until constant weight is achieved. Molecular weights are determined as described before.


example	macroinitiator used	conversion styrene (%)	M _n (initial)	M _n (blockcopolymer)	M _w /M _n
3	1	24	3500	5900	1,27
4	2	24	3300	4400	1,34

Claims

1. A compound of formula Ia, IIa or IIIa



wherein

D is a group  or a group C(O)-R₁₃;

R₁₃ is phenyl or C₁-C₁₈alkyl;


m is 1, 2 or 3;

n is 1 or 2;

if n is 1

Y and Y' are independently C₁-C₁₂alkyl, C₃-C₁₂alkenyl, C₃-C₁₂alkinyl, C₅-C₈cycloalkyl, phenyl, naphthyl, C₇-C₉phenylalkyl; or

Y and Y' together form one of the bivalent groups -C(R₁)(R₂)-CH(R₃)-, CH(R₁)-CH₂-C(R₂)(R₃)-, -CH(R₂)-CH₂-C(R₁)(R₃)-, -CH₂-C(R₁)(R₂)-CH(R₃)-, o-phenylene, 1,2-cyclohexyliden,

-CH₂-CH=CH-CH₂- or  ; wherein


R₁ is hydrogen, C₁-C₁₂alkyl, COOH, COO-(C₁-C₁₂)alkyl or CH₂OR₄;

R₂ and R₃ are independently hydrogen, methyl ethyl, COOH or COO-(C₁-C₁₂)alkyl;

R_4 is hydrogen, C_1 - C_{12} alkyl, benzyl, or a monovalent acyl residue derived from an aliphatic, cycloaliphatic or aromatic monocarboxylic acid having up to 18 carbon atoms;

if n is 2

Y and Y' together form one of the tetravalent groups




Q is a bisacyl residue which is derived from a C_2 - C_{12} dicarboxylic acid or C_1 - C_{12} alkylene;

Z is C_1 - C_{12} alkylene;


the R_{12} are independently of each other H or CH_3 .

2. A compound according to claim 1 wherein D is a group



3. A compound according to claim 1 wherein in the compound of formula Ia, IIa or IIIa

D is a group



m is 1;

n is 1;

Y and Y' are independently C_1 - C_{12} alkyl, C_3 - C_{12} alkenyl, phenyl or benzyl; or


Y and Y' together form one of the bivalent groups $-C(R_1)(R_2)-CH(R_3)-$, $CH(R_1)-CH_2-C(R_2)(R_3)-$, $-CH(R_2)-CH_2-C(R_1)(R_3)-$, $-CH_2-C(R_1)(R_2)-CH(R_3)-$, $-CH_2-CH=CH-CH_2-$ or ;
wherein

R_1 is hydrogen, C_1-C_{12} alkyl, $COO-(C_1-C_{12})$ alkyl or CH_2OR_4 ;

R_2 and R_3 are independently hydrogen, methyl ethyl, or $COO-(C_1-C_{12})$ alkyl;

R_4 is hydrogen, C_1-C_{12} alkyl, benzyl, or a monovalent acyl residue derived from an aliphatic, cycloaliphatic or aromatic monocarboxylic acid having up to 12 carbon atoms and one of the R_{12} is hydrogen and the other is methyl.

4. A compound according to claim 1 wherein in the compound of formula Ia, IIa or IIIa



m is 1;

n is 1 ;

Y and Y' together form one of the bivalent groups $-CH_2-C(R_1)(R_2)-CH(R_3)-$ wherein

R_1 is hydrogen, methyl or ethyl;

R_2 and R_3 are independently hydrogen, methyl ethyl, or $COO-(C_1-C_{12})$ alkyl; and one of the R_{12} is hydrogen and the other is methyl.

5. A compound according to claim 1 which is of formula IIIa.

6. A compound according to claim 1 of formula Ia, IIa or IIIa which is

1.) 2,6-Diethyl-4,4-dimethoxy-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine

2.) 4,4-Diethoxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine

3.) 2,6-Diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-4,4-dipropoxy-piperidine

4.) 4,4-Dibutoxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine

5.) 2,6-Diethyl-4,4-diisobutoxy-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine

- 6.) 2,6-Diethyl-2,3,6-trimethyl-4,4-bis-octyloxy-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 7.) 4,4-Bis-allyloxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 8.) 4,4-Bis-cyclohexyloxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 9.) 4,4-Bis-benzyloxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 10.) 7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 11.) 7,9-Diethyl-2,6,7,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 12.) 2,7,9-Triethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 13.) 7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-2-propyl-1,4-dioxo-8-aza-spiro[4.5]decane
- 14.) 2-Butyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 15.) 7,9-Diethyl-6,7,9-trimethyl-2-octyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 16.) 2-Decyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 17.) 2-Dodecyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 18.) {7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-yl}-methanol
- 19.) Acetic acid 7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 20.) Octadecanoic acid 7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 21.) Benzoic acid 7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 22.) 7,9-Diethyl-2-methoxymethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane

- 23.) 2-Cyclohexyloxymethyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 24.) 2-Benzyloxymethyl-7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 25.) Octanedioic acid bis-{7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester
- 26.) Terephthalic acid bis-{7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester
- 27.) 1',4'-Bis-{7,9-diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl}-oxybutane
- 28.) 7,9-Diethyl-2,2,6,7,9-pentamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 29.) 7,9-Diethyl-2,3,6,7,9-pentamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 30.) 4,4-(o-Phenylendioxy)-2,6-diethyl-2,3,6-trimethyl-1-[1'-(4'-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 31.) 4,4-(1',2'-cyclohexylendioxy)-2,6-diethyl-2,3,6-trimethyl-1-[1''-(4''-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 32.) 7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane-2,3-dicarboxylic acid dimethyl ester
- 33.) 8,10-Diethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 34.) 8,10-Diethyl-3,3,7,8,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 35.) 3,8,10-Triethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 36.) 3,3,8,10-Tetraethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 37.) 8,10-Diethyl-3,3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-3-propyl-1,5-dioxo-9-aza-spiro[5.5]undecane
- 38.) 3-Butyl-3,8,10-triethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 39.) 2,4-Diethyl-1,2,4-trimethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,16-dioxo-3-aza-dispiro[5.2.5.2]hexadec-11-ene

- 40.) {8,10-Diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol
- 41.) {3,8,10-Triethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol
- 42.) 8,10-Diethyl-3-methoxymethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 43.) 3-Cyclohexyloxymethyl-8,10-diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 44.) 3-Benzoyloxymethyl-8,10-diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 45.) Acetic acid 8,10-diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl ester
- 46.) Octanedioic acid bis-{8,10-diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} ester
- 47.) 1',6'-Bis-{3,8,10-triethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} -oxyhexane
- 48.) 8,10-Diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3-carboxylic acid methyl ester
- 49.) 8,10-Diethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3,3-dicarboxylic acid diethyl ester
- 50.) 3,3-Bis-{8,10-diethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 51.) 2,4-Diethyl-1,2,4-trimethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,12-dioxo-3-aza-spiro[5.6]dodec-9-ene
- 52.) 2,2-Diethyl-4,4-dimethoxy-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 53.) 4,4-Diethoxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 54.) 2,2-Diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-4,4-dipropoxy-piperidine
- 55.) 4,4-Dibutoxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 56.) 2,2-Diethyl-4,4-diisobutoxy-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 57.) 2,2-Diethyl-6,6-dimethyl-4,4-bis-octyloxy-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine

- 58.) 4,4-Bis-allyloxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 59.) 4,4-Bis-cyclohexyloxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 60.) 4,4-Bis-benzyloxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 61.) 7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 62.) 7,7-Diethyl-2,9,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 63.) 2,7,7-Triethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 64.) 7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-2-propyl-1,4-dioxo-8-aza-spiro[4.5]decane
- 65.) 2-Butyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 66.) 7,7-Diethyl-9,9-dimethyl-2-octyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 67.) 2-Decyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 68.) 2-Dodecyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 69.) {7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-yl}-methanol
- 70.) Acetic acid 7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 71.) Octadecanoic acid 7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 72.) Benzoic acid 7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 73.) 7,7-Diethyl-2-methoxymethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 74.) 2-Cyclohexyloxymethyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane

- 75.) 2-Benzoyloxymethyl-7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 76.) Octanedioic acid bis-{7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester
- 77.) Terephthalic acid bis-{7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester
- 78.) 1',4'-Bis-{7,7-diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl}-oxybutane
- 79.) 7,7-Diethyl-2,2,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 80.) 7,7-Diethyl-2,3,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 81.) 4,4-(o-Phenylendioxy)-2,2-diethyl-6,6-dimethyl-1-[1'-(4'-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 82.) 4,4-(1',2'-cyclohexylendioxy)-2,2-diethyl-6,6-dimethyl-1-[1''-(4''-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 83.) 7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane-2,3-dicarboxylic acid dimethyl ester
- 84.) 8,8-Diethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 85.) 8,8-Diethyl-3,3,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 86.) 3,8,8-Triethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 87.) 3,3,8,8-Tetraethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 88.) 8,8-Diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-3-propyl-1,5-dioxo-9-aza-spiro[5.5]undecane
- 89.) 3-Butyl-3,8,8-triethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 90.) 2,2-Diethyl-4,4-dimethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,16-dioxo-3-aza-dispiro[5.2.5.2]hexadec-11-ene
- 91.) {8,8-Diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol

- 92.) {3,8,8-Triethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol
- 93.) 8,8-Diethyl-3-methoxymethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 94.) 3-Cyclohexyloxymethyl-8,8-diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 95.) 3-Benzoyloxymethyl-8,8-diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 96.) Acetic acid 8,8-diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl ester
- 97.) Octanedioic acid bis-{8,8-diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} ester
- 98.) 1',6'-Bis-{3,8,8-triethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} -oxyhexane
- 99.) 8,8-Diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3-carboxylic acid methyl ester
- 100.) 8,8-Diethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3,3-dicarboxylic acid diethyl ester
- 101.) 3,3-Bis-{8,8-diethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 102.) 2,2-Diethyl-4,4-dimethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,12-dioxo-3-aza-spiro[5.6]dodec-9-ene
- 103.) 4,4-Dimethoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 104.) 4,4-Diethoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 105.) 2,2,6,6-Tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-4,4-dipropoxy-piperidine
- 106.) 4,4-Dibutoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 107.) 4,4-Diisobutoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 108.) 2,2,6,6-Tetramethyl-4,4-bis-octyloxy-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 109.) 4,4-Bis-allyloxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 110.) 4,4-Bis-cyclohexyloxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 111.) 4,4-Bis-benzyloxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine

- 112.) 7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 113.) 2,7,7,9,9-Pentamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 114.) 2-Ethyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 115.) 7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-2-propyl-1,4-dioxo-8-aza-spiro[4.5]decane
- 116.) 2-Butyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 117.) 7,7,9,9-Tetramethyl-2-octyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 118.) 2-Decyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 119.) 2-Dodecyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 120.) {7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-yl}-methanol
- 121.) Acetic acid 7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 122.) Octadecanoic acid 7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 123.) Benzoic acid 7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl ester
- 124.) 2-Methoxymethyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 125.) 2-Cyclohexyloxymethyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 126.) 2-Benzyloxymethyl-7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 127.) Octanedioic acid bis-{7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester
- 128.) Terephthalic acid bis-{7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl} ester

- 129.) 1',4'-Bis-{7,7,9,9-tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]dec-2-ylmethyl}-oxybutane
- 130.) 2,2,7,7,9,9-Hexamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 131.) 2,3,7,7,9,9-Hexamethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane
- 132.) 4,4-(o-Phenylendioxy)-2,2,6,6-tetramethyl-1-[1'-(4'-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 133.) 4,4-(1',2'-cyclohexylendioxy)-2,2,6,6-tetramethyl-1-[1''-(4''-oxiranylmethoxy-phenyl)-ethoxy]-piperidine
- 134.) 7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane-2,3-dicarboxylic acid dimethyl ester
- 135.) 8,8,10,10-Tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 136.) 3,3,8,8,10,10-Hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 137.) 3-Ethyl-3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 138.) 3,3-Diethyl-8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 139.) 3,8,8,10,10-Pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-3-propyl-1,5-dioxo-9-aza-spiro[5.5]undecane
- 140.) 3-Butyl-3-ethyl-8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 141.) 2,2,4,4-Tetramethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,16-dioxo-3-aza-dispiro[5.2.5.2]hexadec-11-ene
- 142.) {3,8,8,10,10-Pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol
- 143.) {3-Ethyl-8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol
- 144.) 3-Methoxymethyl-3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 145.) 3-Cyclohexyloxymethyl-3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane

- 146.) 3-Benzylloxymethyl-3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 147.) Acetic acid 3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl ester
- 148.) Octanedioic acid bis-{3,8,8,10,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} ester
- 149.) 1',6'-Bis-{8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-ylmethyl} -oxyhexane
- 150.) 3,8,8,10,10-Pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3-carboxylic acid methyl ester
- 151.) 8,8,10,10-Tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane-3,3-dicarboxylic acid diethyl ester
- 152.) 3,3-Bis-{8,8,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane
- 153.) 2,2,4,4-Tetramethyl-3-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-7,12-dioxo-3-aza-spiro[5.6]dodec-9-ene

7. A compound according to claim 6 of formula Ia, IIa or IIIa which is

- 4,4-Dibutoxy-2,6-diethyl-2,3,6-trimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine;
- 7,9-Diethyl-6,7,9-trimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane;
- 8,10-Diethyl-3,3,7,8,10-pentamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane;
- {8,10-Diethyl-3,7,8,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol;
- {3,8,10-Triethyl-7,8,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol;
- 4,4-Dibutoxy-2,2-diethyl-6,6-dimethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine;
- 7,7-Diethyl-9,9-dimethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane;
- 8,8-Diethyl-3,3,10,10-tetramethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane;
- {8,8-Diethyl-3,10,10-trimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol;

{3,8,8-Triethyl-10,10-dimethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl}-methanol;


4,4-Dibutoxy-2,2,6,6-tetramethyl-1-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-piperidine;

7,7,9,9-Tetramethyl-8-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,4-dioxo-8-aza-spiro[4.5]decane;


3,3,8,8,10,10-Hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane.

8. A polymerizable composition, comprising

- a) at least one ethylenically unsaturated monomer or oligomer, and
- b) a compound of formula Ia, IIa or IIIa



wherein

D is a group  or a group C(O)-R₁₃;

R₁₃ is phenyl or C₁-C₁₈alkyl;


m is 1, 2 or 3;

n is 1 or 2;

if n is 1

Y and Y' are independently C₁-C₁₂alkyl, C₃-C₁₂alkenyl, C₃-C₁₂alkinyl, C₅-C₈cycloalkyl, phenyl, naphthyl, C₇-C₉phenylalkyl; or

Y and Y' together form one of the bivalent groups $-C(R_1)(R_2)-CH(R_3)-$, $CH(R_1)-CH_2-C(R_2)(R_3)-$, $-CH(R_2)-CH_2-C(R_1)(R_3)-$, $-CH_2-C(R_1)(R_2)-CH(R_3)-$, o-phenylene, 1,2-cyclohexylenidene,




R_1 is hydrogen, C_1-C_{12} alkyl, $COOH$, $COO-(C_1-C_{12})$ alkyl or CH_2OR_4 ;

R_2 and R_3 are independently hydrogen, methyl ethyl, $COOH$ or $COO-(C_1-C_{12})$ alkyl;

R_4 is hydrogen, C_1-C_{12} alkyl, benzyl, or a monovalent acyl residue derived from an aliphatic, cycloaliphatic or aromatic monocarboxylic acid having up to 18 carbon atoms;

if n is 2

Y and Y' together form one of the tetravalent groups



Q is a bisacyl residue which is derived from a C_2-C_{12} dicarboxylic acid or C_1-C_{12} alkylene;

Z is C_1-C_{12} alkylene;

the R_{12} are independently of each other H or CH_3 .


9. A polymerizable composition according to claim 8, wherein the ethylenically unsaturated monomers or oligomers are selected from the group consisting of styrene, substituted

styrene, conjugated dienes, acrolein, vinyl acetate, (alkyl)acrylic acid anhydrides, (alkyl)acrylic acid salts, (alkyl)acrylic esters or (alkyl)acrylamides.

10. A polymerizable composition according to claim 9, wherein the ethylenically unsaturated monomers are styrene, α -methyl styrene, p-methyl styrene, butadiene, methylacrylate, ethylacrylate, propylacrylate, n-butyl acrylate, tert.-butyl acrylate and acrylonitril.


11. A polymerizable composition according to claim 8, wherein the compound of formula Ia, IIa or IIIa is present in an amount of from 0.01 mol-% to 20 mol-% based on the monomer.

12. A process for preparing an oligomer, a cooligomer, a polymer or a copolymer (block or random) by free radical polymerization of at least one ethylenically unsaturated monomer or oligomer, which comprises (co)polymerizing the monomer or monomers/oligomers in the presence of an initiator compound of formula Ia, IIa or IIIa under reaction conditions capable of effecting scission of the O-C bond to form two free radicals, the radical




13. A process according to claim 12, wherein the scission of the O-C bond is effected by heating and takes place at a temperature of between 50°C and 160°C.

14. A polymer or oligomer, containing at least one initiator group




and at least one oxyamine group of formula Ib, IIb or IIIb


- 82 -



(Ib)



(IIb)




(IIIb)

wherein n , Y and Y' are as defined in claim 1, obtainable by the process according to claim 12.


15. Use of a compound of formula Ia, IIa or IIIa according to claim 1 for polymerizing ethylenically unsaturated monomers.

16. Use of a compound of formula Ia, IIa or IIIa according to claim 1 for terminating the anionic polymerization of a diene or vinyl monomer.


17. A compound according to formula Xd, XIId or XIId



(Xd)



(XIId)



(XIIId)

wherein Y , Y' , R_{12} and n are defined as in claim 1.

•
•
•

(

5

5

(

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/048109 A3

(51) International Patent Classification⁷: C07D 211/94,
C08F 2/00, C07D 491/10, 491/22, 519/00, 405/12

(21) International Application Number: PCT/EP01/13071

(22) International Filing Date:
12 November 2001 (12.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00811191.6 14 December 2000 (14.12.2000) EP

(71) Applicant (*for all designated States except US*): CIBA
SPECIALTY CHEMICALS HOLDING INC. [CH/CH];
Klybeckstrasse 141, CH-4057 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): FUSO, Francesco
[IT/CH]; Bienenweg 8, CH-4106 Therwil (CH). WUN-
DERLICH, Wiebke [DE/IT]; Via Valdossola 28, I-40134
Bologna (IT). KRAMER, Andreas [CH/CH]; Rue Os-
car-Patthey 45, CH-3280 Meyriez (CH). FINK, Jochen
[DE/DE]; Kurt-Schumacherstrasse 16, 69226 Nussloch
(DE).

(74) Common Representative: CIBA SPECIALTY CHEMI-
CLAS HOLDING INC.; Patentabteilung, Klybeckstrasse
141, CH-4057 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
29 August 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINES AS POLYMERISATION INHIBITORS

(57) Abstract: The present invention relates to selected glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds forming an open chain or cyclic ketal structure, a polymerizable composition comprising a) at least one ethylenically unsaturated monomer and b) a glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine nitroxide initiator compound. Further aspects of the present invention are a process for polymerizing ethylenically unsaturated monomers and the use of glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine nitroxide initiators for radical polymerization.

WO 02/048109 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/13071

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/94 C08F2/00 C07D491/10 C07D491/22 C07D519/00
C07D405/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C08F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 46261 A (FUSO FRANCESCO ;CIBA SC HOLDING AG (CH); WUNDERLICH WIEBKE (DE); R) 16 September 1999 (1999-09-16) cited in the application the whole document	1,8,12, 14-17
A	US 4 921 962 A (GALBO JAMES P ET AL) 1 May 1990 (1990-05-01) examples 10,11	1,17

☐ Further documents are listed in the continuation of box C.


Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

11 June 2002

Date of mailing of the international search report

20/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Diederer, J

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 01/13071

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9946261	A	16-09-1999	AT 408655 B	25-02-2002
			AT 38799 A	15-06-2001
			AU 1863699 A	23-09-1999
			AU 2929699 A	27-09-1999
			BE 1012399 A3	03-10-2000
			BR 9900977 A	21-03-2000
			CA 2321792 A1	16-09-1999
			CN 1228424 A	15-09-1999
			CZ 9900789 A3	15-09-1999
			DE 19909767 A1	16-09-1999
			WO 9946261 A1	16-09-1999
			EP 1071681 A1	31-01-2001
			ES 2155014 A1	16-04-2001
			FR 2777892 A1	29-10-1999
			GB 2335190 A , B	15-09-1999
			IT MI990453 A1	05-09-2000
			JP 11322714 A	24-11-1999
			JP 2002506070 T	26-02-2002
			NL 1011493 C2	28-10-1999
			NL 1011493 A1	10-09-1999
			SG 82601 A1	21-08-2001
			US 6353107 B1	05-03-2002
US 4921962	A	01-05-1990	NONE	

(

THIS PAGE BLANK (USPTO)

(

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)